about
Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine TrialsThe genetic basis for cancer treatment decisionsEnhancing reproducibility in cancer drug screening: how do we move forward?Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS).Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?Tumour heterogeneity in the clinic.Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.Spinal cord stimulators and radiotherapy: first case report and practice guidelinesLuminal-B breast cancer and novel therapeutic targets.Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer TherapyDecoding the evolution of a breast cancer genomeMatters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancerA phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).Quality of life and understanding of disease status among cancer patients of different ethnic originA phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.Are we HER-ting for innovation in neoadjuvant breast cancer trial design?Recent advances in adjuvant systemic therapy for early-stage breast cancer.Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer.International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.Stemming resistance to HER-2 targeted therapy.A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.Clinical application of high-throughput genomic technologies for treatment selection in breast cancer.Therapeutic management of breast cancer in the elderly.Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?Stage II seminomas and nonseminomas.Cancer genomics: technology, discovery, and translation.
P50
Q26776394-E1837B3E-824A-4BE9-B6CB-53209C10D06BQ26849200-1DAF103F-8366-4C3F-B1C7-7853C06F1E70Q30405622-8AD40EE9-FEE1-4A30-B134-1B50A58023A4Q30826387-30D326FF-8BA2-4C71-92D5-80D9E73CC4CCQ33697985-82539547-50B6-4E75-AB50-046CA56DA3F2Q34033475-016D2C5B-9A57-466A-B8E5-58FCA45F0074Q34040965-C7FBF59A-FA13-4DC5-8360-D2176AFC3130Q34372080-F4145FCE-DEC5-43F9-AF98-2D7C58259912Q34433731-6A57B69E-06AD-4B2E-AE23-52E17316A4C0Q34661188-BE12C150-14B8-4F31-A9CB-F700C5179710Q35098333-A526D0DC-9AA8-46BC-BFB2-EBF7BA48232DQ35602740-10596BFC-5C72-4189-9F0E-D152B06DE90AQ35889534-1F1E5D0C-88FA-4DA7-A101-19D5C4231EB7Q35898422-43EB7F94-E78B-465F-9AC2-C8DE175784B5Q35963154-F986B0F1-4B7E-4D56-B7C2-B4D72A9DF62EQ36039142-1704FF4A-58B5-40DA-8EF7-E144270A2B97Q36410651-93B5802D-C11C-4CFC-AB14-3718E84D427CQ36480124-697A74D3-ACF6-4C7C-B317-22D6D6F98645Q36648254-7A19B522-BD57-4739-874E-F59979A682E9Q37111141-EC2DE145-9923-457C-B49E-10F17A61C2A6Q37113821-BE3E22A0-DB0B-47BC-9815-05F157743DABQ37166379-90993533-D3B1-48DC-9F37-095939496AE3Q37205521-18A203F4-BA43-42E2-9CE9-87BBD519A37CQ37210711-9586BEE8-A666-4C9A-A382-F07671F40C7CQ37297706-F062F155-0695-4CE5-BC0D-AB9A5831AE84Q37329165-8E02B43E-E029-47E8-A349-82A3408431C0Q37373983-CF33624A-E127-4641-8C82-2A92EE953297Q37406061-A92D4BE4-ACC3-479E-BA42-71B0FBB11F8CQ37407616-C0720C4E-FB43-439E-B2D3-8391C2087017Q37411697-AFB8EAD4-B043-4D13-A240-0A96A8D494FAQ37471532-F8DCDA20-57D8-44F6-BFBA-DF96386B79D0Q37547954-6996DBBC-1653-4FE7-9B82-4AC270593F8DQ37585888-B304D043-10C1-4F25-BEA0-C60C3B96D6DCQ37649479-BC05F762-C1B6-4DBE-80B6-CB2942727A66Q37651820-95832138-C829-4CB0-B9D3-AB6615580511Q37691245-4671558A-8D63-4A3A-A420-31FBE4D16E6BQ37842506-BB15494A-BCF3-4ACE-B9DA-F1541C27FB0FQ37848654-3A9E66E1-E461-4900-A95A-DFED3B09895DQ37875409-1C66ED63-310F-4625-BA1E-A52B97E99A06Q37978247-79B51B60-1C6D-4F93-9954-3112662E62B1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Philippe L. Bedard
@ast
Philippe L. Bedard
@en
Philippe L. Bedard
@es
Philippe L. Bedard
@nl
Philippe L. Bedard
@sl
type
label
Philippe L. Bedard
@ast
Philippe L. Bedard
@en
Philippe L. Bedard
@es
Philippe L. Bedard
@nl
Philippe L. Bedard
@sl
prefLabel
Philippe L. Bedard
@ast
Philippe L. Bedard
@en
Philippe L. Bedard
@es
Philippe L. Bedard
@nl
Philippe L. Bedard
@sl
P106
P1153
26643053500
P21
P31
P496
0000-0002-6771-2999